Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: Metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 709-715

  Chin, Chih Liang ^a   Upadhyay, Jaymin ^a   Marek, Gerard J ^a   Baker, Scott J ^a   Zhang, Min ^a   Mezler, Mario ^b   Fox, Gerard B ^a   Day, Mark ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BIOLOGICAL MARKER; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; GLUTAMATE RECEPTOR AGONIST; KETAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD OXYGENATION LEVEL DEPENDENCE SIGNAL; BRAIN CORTEX; BRAIN FUNCTION; CARDIOVASCULAR PARAMETERS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; ENTORHINAL CORTEX; HIPPOCAMPUS; MALE; MODULATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIAQUEDUCTAL GRAY MATTER; PHARMACOLOGICAL MAGNETIC RESONANCE IMAGING; POSTERIOR CINGULATE; PRIORITY JOURNAL; RAT; RETROSPLENIAL CORTEX; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WAKEFULNESS;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; BRAIN; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; PILOT PROJECTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; WAKEFULNESS;

EID: 79951963064     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173880     Document Type: Article

References (40)

1. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, Brammer MJ, and Phillips ML (2003) Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 14:387-391. (Pubitemid 36337936)
2. Austin VC, Blamire AM, Allers KA, Sharp T, Styles P, Matthews PM, and Sibson NR (2005) Confounding effects of anesthesia on functional activation in rodent brain: a study of halothane and α-chloralose anesthesia. Neuroimage 24:92-100. (Pubitemid 39611029)
3. Becker A and Grecksch G (2004) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 28:1267-1277.
4. Borsook D, Becerra L, and Hargreaves R (2006) A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5:411-424.
5. Chin CL, Pauly JR, Surber BW, Skoubis PD, McGaraughty S, Hradil VP, Luo Y, Cox BF, and Fox GB (2008a) Pharmacological MRI in awake rats predicts selective binding of α4β2 nicotinic receptors. Synapse 62:159-168. (Pubitemid 351186396)
6. Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, et al. (2008b) Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol 153:367-379.
7. Cox RW (1996) AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29:162-173.
8. Day M, Balci F, Wan HI, Fox GB, Rutkowski JL, and Feuerstein G (2008) Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Curr Opin Investig Drugs 9:696-706. (Pubitemid 351950866)
9. Day M, Rutkowski JL, and Feuerstein GZ (2009) Translational medicine-a paradigm shift in modern drug discovery and development: the role of biomarkers. Adv Exp Med Biol 655:1-12.
10. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, and Dursun SM (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmacomagnetic resonance imaging study. Arch Gen Psychiatry 65:154-164. (Pubitemid 351214314)
11. Duncan GE, Leipzig JN, Mailman RB, and Lieberman JA (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812:65-75. (Pubitemid 29005332)
12. Ellison G (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-267.
13. Ferris CF, Stolberg T, Kulkarni P, Murugavel M, Blanchard R, Blanchard DC, Febo M, Brevard M, and Simon NG (2008) Imaging the neural circuitry and chemical control of aggressive motivation. BMC Neurosci 9:111.
14. Feuerstein GZ, Gill D, Dormer C, Ruffolo RR, Rutkowski JL, Walsh FS, and Hurko O (2008) The vastly neglected biomarkers contributing to early clinical development failure. Am Pharm Rev 11:64-68.
15. Fox GB, Chin CL, Luo F, Day M, and Cox BF (2009) Translational neuroimaging of the CNS: novel pathways to drug development. Mol Interv 9:302-313.
16. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, and Bifone A (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33:1690-1703. (Pubitemid 351684709)
17. Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, Grier MD, Avison M, Conn PJ, and Gore JC (2010) Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 168:209-218.
18. Holcomb HH, Lahti AC, Medoff DR, Cullen T, and Tamminga CA (2005) Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30:2275-2282. (Pubitemid 41643980)
19. Honey GD, Honey RA, O'Loughlin C, Sharar SR, Kumaran D, Suckling J, Menon DK, Sleator C, Bullmore ET, and Fletcher PC (2005) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15:749-759. (Pubitemid 40703969)
20. Imre G (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev 13:444-464.
21. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, et al. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179:303-309. (Pubitemid 40576718)
22. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
23. Lahti AC, Koffel B, LaPorte D, and Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
24. Lahti KM, Ferris CF, Li F, Sotak CH, and King JA (1999) Comparison of evoked cortical activity in conscious and propofol-anesthetized rats using functional MRI. Magn Reson Med 41:412-416. (Pubitemid 29104530)
25. Långsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Sipilä H, Kurki T, Silvanto M, and Scheinin H (2003) Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99:614-623. (Pubitemid 37051976)
26. Littlewood CL, Jones N, O'Neill MJ, Mitchell SN, Tricklebank M, and Williams SC (2006) Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology 186:64-81. (Pubitemid 43668312)
27. Lockhart SH, Cohen Y, Yasuda N, Freire B, Taheri S, Litt L, and Eger EI 2nd (1991) Cerebral uptake and elimination of desflurane, isoflurane, and halothane from rabbit brain: an in vivo NMR study. Anesthesiology 74:575-580.
28. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, and Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706. (Pubitemid 36263162)
29. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, and Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150. (Pubitemid 27365955)
30. Marek GJ (2004) Metabotropic glutamate 2/3 receptors as drug targets. Curr Opin Pharmacol 4:18-22.
31. Moghaddam B, Adams B, Verma A, and Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927. (Pubitemid 27155025)
32. Nishizawa N, Nakao S, Nagata A, Hirose T, Masuzawa M, and Shingu K (2000) The effect of ketamine isomers on both mice behavioral responses and c-Fos expression in the posterior cingulate and retrosplenial cortices. Brain Res 857:188-192. (Pubitemid 30107805)
33. Olney JW, Newcomer JW, and Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
34. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107. (Pubitemid 47517511)
35. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
36. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, and Brooks WM (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162:394-396. (Pubitemid 40216226)
37. Schoepp D and Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1:215-225.
38. Sharp FR, Jasper P, Hall J, Noble L, and Sagar SM (1991) MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30:801-809.
39. Strum DP, Johnson BH, and Eger EI 2nd (1986) Elimination of anesthetics from rabbit brain. Science 234:1586-1588.
40. Wong DF, Tauscher J, and Gründer G (2009) The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 34:187-203.